Novocure Ltd

NASDAQ NVCR

Data sourced from

and

Daily

Download Data

Novocure Ltd Market Capitalization on June 03, 2024: USD 2.57 B

Novocure Ltd Market Capitalization is USD 2.57 B on June 03, 2024, a -70.71% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Novocure Ltd 52-week high Market Capitalization is USD 8.78 B on June 05, 2023, which is 241.41% above the current Market Capitalization.
Novocure Ltd 52-week low Market Capitalization is USD 1.19 B on November 10, 2023, which is -53.74% below the current Market Capitalization.
Novocure Ltd average Market Capitalization for the last 52 weeks is USD 2.21 B.

NASDAQ: NVCR

Novocure Ltd

CEO	Mr. William F. Doyle
IPO Date	Oct. 2, 2015
Location	Jersey
Headquarters	No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
Employees	1,453
Sector	Healthcare
Industry	Medical devices

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Key trends